Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PanGenetics "Experiment" Winding Down, CEO Kevin Johnson to Pursue Asset-Centric Model at Index Ventures

This article was originally published in The Pink Sheet Daily

Executive Summary

The Belgian biotech secured an exit for investors with last year's unusual front-end loaded NGF deal with Abbott, but lightning won't strike twice as its second program can't get through Phase I.

You may also be interested in...



Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma

Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.

Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma

Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.

People In The News: Tracking The Latest Industry Personnel Moves

Presidents and CEOs

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS071196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel